Comparative Pharmacology
Head-to-head clinical analysis: IOPAMIDOL 370 versus RENOGRAFIN 60.
Head-to-head clinical analysis: IOPAMIDOL 370 versus RENOGRAFIN 60.
IOPAMIDOL-370 vs RENOGRAFIN-60
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iopamidol is a nonionic, water-soluble, iodinated radiographic contrast agent that attenuates X-rays, thereby enhancing vascular and tissue contrast during imaging procedures. Its mechanism is physical rather than pharmacological, based on iodine content and osmolality.
RENOGRAFIN-60 (diatrizoate meglumine and diatrizoate sodium) is an ionic, high-osmolality, iodinated contrast agent. It enhances radiographic contrast by absorbing X-rays due to the high atomic number of iodine. It distributes into the intravascular space and is excreted primarily by the kidneys via glomerular filtration without significant tubular reabsorption or secretion.
1-2 mL/kg (370 mg iodine/mL) IV up to a maximum of 150 mL per procedure for contrast-enhanced CT; for angiography, dose varies by procedure.
Intravenous: 50-100 mL of a 60% solution as a single dose for CT or angiography. Intra-arterial: 5-50 mL depending on vessel size. Maximum total dose: 3 mL/kg.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours (range 1.5-2.5 hours) in patients with normal renal function. Prolonged to 10-70 hours in patients with renal impairment, necessitating dose adjustment or avoidance.
Terminal elimination half-life: 1-2 hours in normal renal function. Prolonged in renal impairment: up to 50 hours. Clinically significant for timing of contrast imaging and risk of contrast-induced nephropathy.
Primarily renal; >90% of administered dose excreted unchanged in urine via glomerular filtration within 24-48 hours. Less than 1% excreted in feces or bile.
Renal: 95-100% (glomerular filtration, no tubular reabsorption). Biliary/Fecal: negligible.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent